Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.78 HKD | +2.47% | -0.74% | -39.19% |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.19% | 1.51B | B- | ||
+17.30% | 83.16B | C+ | ||
-26.28% | 73.08B | B- | ||
-1.34% | 26.15B | C+ | ||
+4.31% | 17.9B | A- | ||
-9.26% | 17.39B | B | ||
+4.08% | 15.94B | A- | ||
+76.90% | 13.61B | C- | ||
+76.96% | 13.06B | C+ | ||
-25.26% | 12.76B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1833 Stock
- Ratings Ping An Healthcare and Technology Company Limited